ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

A number of other research firms have also recently weighed in on ZIOP. Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, April 26th. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, HC Wainwright began coverage on ZIOPHARM Oncology in a research report on Thursday, June 1st. They set a “buy” rating and a $9.50 price objective on the stock. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $13.17.

Shares of ZIOPHARM Oncology (ZIOP) traded down 0.34% during midday trading on Tuesday, hitting $5.94. The stock had a trading volume of 466,507 shares. ZIOPHARM Oncology has a 12 month low of $4.55 and a 12 month high of $7.88. The firm’s market cap is $835.35 million. The stock’s 50 day moving average price is $5.92 and its 200 day moving average price is $6.35.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. During the same period in the previous year, the firm earned ($1.01) earnings per share. The firm’s quarterly revenue was down 5.9% on a year-over-year basis. On average, equities analysts forecast that ZIOPHARM Oncology will post ($0.54) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/08/ziopharm-oncology-inc-nasdaqziop-lifted-to-hold-at-bidaskclub.html.

Hedge funds have recently modified their holdings of the stock. Third Security LLC acquired a new stake in shares of ZIOPHARM Oncology during the fourth quarter valued at about $51,946,000. Vanguard Group Inc. increased its stake in shares of ZIOPHARM Oncology by 5.7% in the first quarter. Vanguard Group Inc. now owns 7,310,537 shares of the biotechnology company’s stock valued at $46,348,000 after buying an additional 396,678 shares during the period. LMM LLC increased its stake in shares of ZIOPHARM Oncology by 21.3% in the fourth quarter. LMM LLC now owns 4,793,896 shares of the biotechnology company’s stock valued at $39,838,000 after buying an additional 840,299 shares during the period. State Street Corp increased its stake in shares of ZIOPHARM Oncology by 0.6% in the first quarter. State Street Corp now owns 4,039,207 shares of the biotechnology company’s stock valued at $25,607,000 after buying an additional 22,864 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its stake in shares of ZIOPHARM Oncology by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,045,989 shares of the biotechnology company’s stock valued at $22,601,000 after buying an additional 17,982 shares during the period. 38.20% of the stock is currently owned by institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.